Cardiac Dimensions develops minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure. Credit: Cardiac Dimensions.

Cardiac Dimensions has secured $17.5m in Series C financing round to accelerate the commercial sales of its Carillon Mitral Contour System in Europe.

The company will also use the funds to enter new markets such as Australia.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The latest round was joined by all existing shareholders of the company, including Aperture Venture Partners, Arboretum Ventures, Hostplus, Life Sciences Partners, Lumira Ventures, and M H Carnegie & Co.

Cardiac Dimensions develops minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure.

The company’s Carillon System is designed to reshape the anatomy and function of the mitral apparatus from the coronary sinus. It is developed to treat the major cause of FMR in patients with MR grades 2+, 3+ and 4+.

Earlier this month, Cardiac Dimensions received approval from Australia’s Therapeutic Goods Administration for the Carillon System for commercial use in FMR patients with mild to severe mitral regurgitation. The system was granted CE Mark in 2011.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Cardiac Dimensions CEO and president Rick Wypych said: “The Carillon System is a transformative product, which has shown great success in helping an extremely large patient population with very few options.

“The new round of financing will allow for continued growth of sales in Europe and provide capital for our expansion efforts into other geographies such as Australia. We thank our investors for their continued support as our business shows excellent results despite the challenging environment.”

It is estimated that 26 million people suffer from heart failure globally while nearly 70% of them have FMR.

H Carnegie & Co spokesperson Trevor Moody said: “We’re excited to support the expansion of sales of the Carillon System.

“Cardiac Dimensions’ innovative efforts and dedication to expanding access to the Carillon System will soon allow people worldwide to benefit from this therapeutic innovation.”